Skip to main content
Federal & State Lawfederalstatelaw.com
Home/Federal/Bills (Live)
HOUSE 5074118th CongressReported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.

Kidney PATIENT Act of 2023

Last Action
6/11/2024

Actions

  • 2024-06-11Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.
  • 2024-06-11Reported (Amended) by the Committee on Ways and Means. H. Rept. 118-548, Part I.
  • 2024-03-20Ordered to be Reported (Amended) by the Yeas and Nays: 37 - 10.
  • 2024-03-20Committee Consideration and Mark-up Session Held
  • 2024-03-12Forwarded by Subcommittee to Full Committee by the Yeas and Nays: 16 - 10.
  • 2024-03-12Subcommittee Consideration and Mark-up Session Held
  • 2024-03-06Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 41 - 1.
  • 2024-03-06Committee Consideration and Mark-up Session Held
  • 2024-03-06Committee Consideration and Mark-up Session Held
  • 2023-08-04Referred to the Subcommittee on Health.
  • 2023-07-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2023-07-28Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2023-07-28Introduced in House
  • 2023-07-28Introduced in House

CRS Summary

As of 2023-07-28 (00)

Kidney Patient Access to Technologically Innovative and Essential Nephrology Treatments Act of 2023 or the Kidney PATIENT Act of 2023

This bill delays a change to the payment methodology under Medicare for oral drugs that are used to treat end-stage renal disease (ESRD).

Under current regulations, beginning January 1, 2025, the Centers for Medicare & Medicaid Services will incorporate payments for oral-only ESRD drugs into the ESRD prospective payment system rather than issuing separate payments to ESRD facilities. The bill delays implementation of this policy until January 1, 2033, or until an approved intravenous drug is available, whichever is earlier.

Cosponsors (20)

  • Ann Kuster (D-NH)
  • Carol Miller (R-WV)
  • Terri Sewell (D-AL)
  • Donald Davis (D-NC)
  • Yvette Clarke (D-NY)
  • John Joyce (R-PA)
  • A. Ferguson (R-GA)
  • DANNY DAVIS (D-IL)
  • Blake Moore (R-UT)
  • Henry Cuellar (D-TX)
  • Jodey Arrington (R-TX)
  • Henry Johnson (D-GA)
  • Larry Bucshon (R-IN)
  • William Keating (D-MA)
  • Stephen Lynch (D-MA)
  • Jonathan Jackson (D-IL)
  • Seth Moulton (D-MA)
  • Jasmine Crockett (D-TX)
  • Vince Fong (R-CA)
  • Mike Thompson (D-CA)

Subjects

  • Digestive and metabolic diseases
  • Health care costs and insurance
  • Medicare
  • Prescription drugs
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.